Skip to main content

Advertisement

SpringerLink
Log in

Clinical significance of [18F]-fluoro-deoxy-glucose positron emission tomography/computed tomography in patients with primary malignant melanoma of the esophagus: report of three cases

  • Case Report
  • Published:
Esophagus Aims and scope Submit manuscript

Abstract

Primary malignant melanoma of the esophagus (PMME) is a rare disease with poor prognosis. [18F]-Fluoro-deoxy-glucose positron emission tomography (FDG-PET) has been used extensively for initial tumor staging, therapeutic monitoring, and follow-up evaluation in various malignant tumors, but the significance of FDG-PET in PMME is currently unknown. Herein, we report 3 cases of PMME. In all 3 cases, histological and immunohistochemical examination of the biopsy specimens led to diagnoses of malignant melanoma. FDG-PET/computed tomography was performed in all cases, and was useful for the detection of distant metastases. However, the identification of lymph node metastases at initial diagnosis was difficult. Esophagectomy was performed in one case, while systemic chemotherapy was administered in 2 cases. All 3 patients had a poor prognosis; the mean survival time was 13.3 months. In conclusion, PET/computed tomography is useful for the detection of distant metastasis at initial diagnosis as well as the therapeutic monitoring of PMME.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Suzuki H, Nagayo T. Primary tumors of the esophagus other than squamous cell carcinoma-histologic classification and statistics in the surgical and autopsied materials in Japan. Int Adv Surg Oncol. 1980;3:73–109.

    CAS  PubMed  Google Scholar 

  2. Sabanathan S, Eng J, Pradhan GN. Primary malignant melanoma of the esophagus. Am J Gastroenterol. 1989;84:1475–81.

    CAS  PubMed  Google Scholar 

  3. Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2006;24:1178–87.

    Article  PubMed  Google Scholar 

  4. Allen AC, Spitz S. Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1–45.

    Article  CAS  PubMed  Google Scholar 

  5. Patel P, Finger PT. Whole-body 18F FDG positron emission tomography/computed tomography evaluation of patients with uveal metastasis. Am J Ophthalmol. 2012;153(4):661–8.

    Article  PubMed  Google Scholar 

  6. Schöder H, Larson SM, Yeung HW. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med. 2004;45(Suppl 1):72S–81S.

    PubMed  Google Scholar 

  7. Freudenberg LS, Schueler AO, Beyer T, et al. Whole-body fluorine-18 fluordeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma. Surv Ophthalmol. 2004;49(5):537–40.

    Article  CAS  PubMed  Google Scholar 

  8. Finger PT, Kurli M, Reddy S, et al. Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol. 2005;89(10):1270–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Strobel K, Dummer R, Husarik DB, et al. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology. 2007;244(2):566–74.

    Article  PubMed  Google Scholar 

  10. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-d-glucose positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104(3):570–9.

    Article  PubMed  Google Scholar 

  11. Veit-Haibach P, Vogt FM, Jablonka R, et al. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging. 2009;36(6):910–8.

    Article  PubMed  Google Scholar 

  12. Li B, Lei W, Shao K, et al. Characteristics and prognosis of primary malignant melanoma of the esophagus. Melanoma Res. 2007;17(4):239–42.

    Article  PubMed  Google Scholar 

  13. Lens MB, Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother. 2003;4(12):2205–11.

    Article  CAS  PubMed  Google Scholar 

  14. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.

    Article  CAS  PubMed  Google Scholar 

  16. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Gunma Prefectural Cancer Center, Ota, Gunma, Japan

    Akihiko Sano, Hitoshi Ojima, Daigo Ozawa, Atsushi Ogawa, Hiroyuki Ando, Yasuyuki Fukai & Yasushi Mochida

  2. Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan

    Makoto Sohda & Hiroyuki Kuwano

Authors
  1. Akihiko Sano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hitoshi Ojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daigo Ozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atsushi Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroyuki Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Makoto Sohda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuyuki Fukai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yasushi Mochida
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroyuki Kuwano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akihiko Sano.

Ethics declarations

Ethical Statement

All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or its substitute was obtained from all patients included in the study.

Conflict of interest

The authors have no conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sano, A., Ojima, H., Ozawa, D. et al. Clinical significance of [18F]-fluoro-deoxy-glucose positron emission tomography/computed tomography in patients with primary malignant melanoma of the esophagus: report of three cases. Esophagus 13, 311–316 (2016). https://doi.org/10.1007/s10388-016-0529-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10388-016-0529-5

Keywords

Search

Navigation